Department of Thoracic Surgery, University Hospital Zurich, Raemistrasse 100, Zurich 8091, Switzerland.
Department of Thoracic Surgery, University Hospital Zurich, Raemistrasse 100, Zurich 8091, Switzerland.
Thorac Surg Clin. 2020 Nov;30(4):435-449. doi: 10.1016/j.thorsurg.2020.08.003.
In the absence of standardized treatment algorithms for patients with malignant pleural mesothelioma, one of the main difficulties remains patient allocation to therapies with potential benefit. This article discusses clinical, radiologic, pathologic, and molecular prognostic factors as well as genetic background leading to preoperative identification of benefit from surgery, which have been investigated over the past years to simplify and at the same time specify patient selection for surgical treatment.
在缺乏恶性胸膜间皮瘤患者标准化治疗方案的情况下，主要困难之一仍然是将患者分配到具有潜在获益的治疗方法中。本文讨论了近年来为简化和同时明确手术治疗患者选择而进行的临床、影像学、病理学和分子预后因素以及导致术前确定手术获益的遗传背景的研究。
